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Case presentation
A 28-year-old white man was evaluated for progressive deterioration of
renal function. At age 17, he presented with symptoms of the nephrotic
syndrome. Evaluation at that time included a blood pressure of 135/90 mm
Hg; serum creatinine, 1.5 mg/dl; creatinine clearance, 81 mI/mm; urine
protein, 6.3 g/24 hr; serum albumin, 3.1 g/dl; serum cholesterol, 325 mgldl;
triglycerides, 220 mgldl; low-density lipoprotein (LDL) cholesterol, 240
mg/dl; and a high-density lipoprotein (HDL) of 32 mgldl. A renal biopsy
demonstrated histopathologic changes consistent with focal and segmental
glomerulosclerosis. The patient was treated briefly with a course of
prednisone without clinical benefit. His blood pressure was effectively
treated with various antihypertensive agents and was usually recorded as
<160/90mm Hg during followup visits. Modest dietary protein restriction
was also prescribed, although his adherence was questionable. Despite
these efforts, his renal function progressively deteriorated over the ensuing
11 years, proteinuria ranged from 3 to 6 g/24 hr, and marked hyperlipid-
emia persisted. During the past 6 months, he has noted left-sided chest
pain, particularly when he was physically active.
Physical examination revealed a chronically ill man who appeared older
than his stated age. His supine blood pressure was 165/95 mm Hg, and his
pulse was 88 beats/mm and regular. Funduscopic examination revealed
increased light reflex and modest arteriovenous nicking but no hemor-
rhages or exudates. Chest examination was unremarkable and the cardiac
examination revealed only an S4 gallop. There was no jugular venous
distention. Abdominal examination was unremarkable and ascites was not
present. Extremities revealed only trace edema, and the rest of the
neurologic examination was unremarkable.
Fasting laboratory studies revealed a creatinine clearance of 15 mI/mm
with a serum creatinine of 6.3 mg/dl. Urinary protein was 4.7 g/24 hr. Total
cholesterol was 315 mg/dl; LDL cholesterol, 248 mg/dl; HDL cholesterol,
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25 mg/dl; triglycerides, 455 mg/dl; and lipoprotein (a) [Lp(a)], 120 mg/dl.
Serum albumin was 3.0 g/dl. An electrocardiogram showed nonspecific
ST-segment and T-wave abnormalities. An exercise tolerance test revealed
significant ST-segment depression in the inferior leads. Coronary angiog-
raphy demonstrated an isolated lesion of the circumflex vessel estimated
to represent an 85% stenosis.
A diagnosis of chronic renal failure secondary to focal glomeruloscle-
rosis with persistent nephrotic-range proteinuria and marked dyslipidemia
was confirmed. In addition, significant coronary artery disease was diag-
nosed. Blood pressure was returned to normal with the addition of an
angiotensin-converting-enzyme inhibitor. On this regimen, his proteinuria
decreased to 2.2 g/24 hr over the next 3 months. The LDL cholesterol also
decreased to 218 mg/dl. Because of the persistent hyperlipidemia and
evidence of atherosclerosis, lovastatin (10 mg at bedtime) was initiated.
Discussion
DR. WILLIAM F. KEANE (Professor and Chair,nan, Department of
Medicine, Hennepin County Medical Center, University of Minne-
sota Medical School, Minneapolis, Minnesota): The case before us
today raises a number of important clinical issues regarding the
role of secondary hyperlipidemia in vascular injury in humans.
Although we lack a clear-cut scientific understanding of its role
clinically, considerable experimental evidence implicates hyper-
lipidemia as a factor in the progressive nature of proteinuric renal
disease [1, 2]. We must address several clinically important
questions. Are patients with proteinuric renal diseases and sec-
ondary hyperlipidemia at greater risk for the early development of
coronary artery disease? If so, can aggressive therapeutic inter-
vention reduce this risk? Does hyperlipidemia contribute to the
progression of renal disease in humans and, if so, how? Does
lipid-lowering therapy retard the progression of human renal
disease? If so, by what mechanism(s)?
Cardiovascular implications of dyslipidemia associated with
proteinuria
Patients with diabetes or essential hypertension who have even
small increases in urinary albumin concentration (microalbumin-
uria) are at significantly greater risk for increased cardiovascular
morbidity and mortality [3, 4]. It is not known whether microalbu-
minuria causes metabolic derangements that, in turn, are respon-
sible for the patient's greater propensity to develop cardiovascular
disease, or whether microalbuminuria is simply the expression of
more generalized cardiovascular disease that involves the kidneys
as well. Recent epidemiologic studies have, however, found
atherogenic abnormalities in the lipid profiles of type-I and
type-lI diabetic patients as well as patients with essential hyper-
tension and microalbuminuria [5—7]. Increased LDL cholesterol
and increased Lp(a) have been reported in a number of studies [8,
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Fig. 1. Potential effects of proteinuria on
dyslipidemia in the nephrotic syndrome.
Abbreviations are: VLDL, vety-low-density
lipoprotein; LDL, low-density lipoprotein; IDL,
intermediate-density lipoprotein; Lp(a),
lipoprotein a: ', increase; L, decrease; ?,
questionable. (From Ref. 11.)
9]. In addition, type-I and type-Il diabetic patients with mi-
croalbuminuria frequently have reduced levels of HDL choles-
terol [8—10]. These abnormalities in lipid profiles occur early in
the clinical course of patients with diabetes or essential hyperten-
sion, usually long before clinical evidence of cardiovascular dis-
ease exists; these lipid abnormalities thus might have pathogenetic
implications. The mechanism(s) whereby subtle changes in the
permselective nature of the filtration barrier contribute to the
lipid changes is unknown, It is possible, however, that genetic
factors link these two abnormalities [5]. Alternatively, the kidneys
themselves might play an important regulatoiy role in lipid
metabolism, which is disturbed with the onset of proteinuria.
As in the case today, nondiabetic patients with overt proteinuria
nearly always have marked abnormalities in their lipid profiles
[11] (Fig. 1); increased LDL cholesterol is the main lipid defect
seen in patients with nephrotic-range proteinuria [11]. Alterations
in LDL composition, including phospholipids and cholesterol
esters as well as increased apolipoprotein (apo) B, have been
described. The level of HDL in nephrotics has been reported as
high, normal, or low. In patients with elevated triglycerides, as in
the patient today, HDL levels usually are reduced [11]. Even when
the levels of HDL are normal, the HDL subtypes are abnormally
distributed; specifically, the level of HDL-2 usually is reduced,
whereas HDL-3 is elevated. Elevated triglyceride levels are fre-
quently seen, especially in patients with severe proteinuria or
reduced renal function. Patients with overt proteinuria also have
elevated Lp(a) levels [12].
The mechanisms of these lipid abnormalities in proteinuric
patients are incompletely understood, but increased synthesis and
altered receptor-dependent and receptor-independent catabolism
have been demonstrated [13, 14] (Fig. 1). Moreover, recent
experimental studies have suggested a direct link between lipid
abnormalities and proteinuria [15]. In these studies, expression of
hypercholesterolemia corresponded to the onset of proteinuria
and usually occurred prior to the onset of reduced serum albumin
levels [15]. Further support for a relationship between proteinuria
and dyslipidemia has been provided by studies in which pharma-
cologic reduction in proteinuria was accompanied by a reduction
in LDL cholesterol and Lp(a) [16]. Indeed, in today's patient,
cholesterol decreased in association with a decline in proteinuria.
Whether nondiabetic patients with persistent proteinuria have
an increased risk for atherosclerosis has been debated for decades
[11]. During the past few years, renewed interest has emerged
regarding the importance of cardiovascular disease in patients
with proteinuria. In a preliminary report of nondiabetic adults
with proteinuria, the relative risk for acute myocardial infarction
and death due to coronary artery disease was more than fivefold
greater than in age- and gender-matched, nondiabetic control
patients [17]. Moreover, in children and young adults with pro-
teinuric renal disease who died at a mean age of 14.9 7.7 years,
more than 75% had evidence of atherosclerosis at autopsy, and
13% had greater than 50% coronary artery occlusions [18].
Unfortunately, lipid analyses were not routinely performed in
these patients. These findings are reminiscent of earlier sporadic
case reports in children with the nephrotic syndrome and athero-
sclerosis [19]. The paucity of prospective epidemiologic data, and
the glaring absence of dietary or pharmacologic studies designed
to reduce circulating lipids and assess cardiovascular end points,
make specific therapeutic recommendations difficult. Nonethe-
less, if clinical experience in one area can be transferred to other
areas, it seems prudent that efforts be directed toward the
reduction of atherogenic lipids in patients with persistent protein-
uria. The available experiences with the various lipid-lowering
agents have been reviewed recently [11, 20].
Do lipids contribute to progressive renal injury?
The relationship between lipid abnormalities and renal disease
has not been studied rigorously. We do have some preliminary
data, however. The incidence of renal disease in patients with the
most common forms of primary hyperlipidemia, although un-
known, is low. One recent report suggested that the prevalence of
microalbuminuria in patients with primary lipid disorders is not
increased [21]. On the other hand, autopsy studies have noted a
significant relationship between global glomeruloscierosis and
atherosclerosis and have suggested a relationship between factors
that contribute to atherosclerosis and those leading to glomeru-
losclerosis [22]. These clinical observations are consistent with
experimental studies in which lipid abnormalities are predomi-
nantly seen as modulators of progressive renal disease rather than
as primary initiators of renal disease. We should remember,
however, that a number of unique abnormalities of lipid metab-
olism, such as those in patients with lecithin-cholesterol acyltrans-
ferase deficiency, are associated with the development of renal
disease. A few case reports have detailed a unique form of
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nephrotic syndrome associated with aneurysmal dilation of gb-
merular capillaries, lipoprotein-containing thrombi in glomerular
capillaries, mesangial expansion, mesangial proliferation, and
glomeruloscierosis associated with increased circulating levels of
apo E [23, 24]. This form of renal disease, termed lipoprotein
glomerulopathy, has been observed in patients without elevated
serum cholesterol levels but in whom apo E levels are increased
[25]. Deposits of apo B and apo E also have been seen by
immunohistochemical techniques in other forms of proteinuric
renal diseases, such as IgA nephropathy [26, 27]. In addition,
foam cells frequently are found in segments of glomeruli under-
going sclerosis in patients with focal gbomerulosclerosis [1]. Foam
cells are believed to result from non-receptor-mediated uptake of
modified lipoproteins by macrophages. The finding of lipoproteins
and foam cells in glomeruli of patients with proteinuria suggests
that lipoproteins might be oxidatively modified, an alteration that
could enhance binding to matrix proteins and result in local
glomerular mesangial deposits [28]. Additional studies will be
needed to support this hypothesis.
Preliminary reports have suggested a relationship between
lipids and the rate of progression of renal disease. In nondiabetic
patients with proteinuria, hypercholesterolemia, and hypertriglyc-
eridemia, the rate of loss of renal function was nearly twofold
greater than in patients without marked hyperlipidemia [29]. This
effect was independent of blood pressure control. In addition, in
black and Hispanic children with the nephrotic syndrome second-
ary to focal glomerulosclerosis, the level of cholesterol at presen-
tation predicted the time to renal failure [30]. Similarly, in a group
of nondiabetic, proteinuric patients with progressive renal insuf-
ficiency, the rate of loss of renal function was twice as great in
patients with elevated lipid levels as in those with normal lipid
levels [31]. The most dramatic association seen was between
elevated apo B levels and a monthly decline in glomerular fil-
tration rate [31]. In addition, these investigators demonstrated a
positive correlation between hypertension and hyperlipidemia.
In type-I diabetic patients with nephropathy, total and LDL
cholesterol levels were independent risk factors for the progres-
sion of renal disease [32]. As in patients with nondiabetic disease,
a correlation also existed between hypertension and hyperlipid-
emia, and both together influenced the progression of renal
disease [32].
A recent retrospective analysis of type-I diabetic patients
enrolled in the Diabetic Retinopathy Study also discerned a
relationship between loss of renal function and hypercholesterol-
emia [33]. Recently, Walker reported an association between
cholesterol and angiotensin II levels in 131 diabetic subjects
followed for as long as 8 years [34]. Although no clear-cut
relationship could be established between the rate of loss of renal
function and hyperlipidemia in this study, the strong interaction
with angiotensin II and blood pressure (the latter being the
principal determinant of progression) likely suggests an important
secondary role of cholesterol [34]. To date, no prospective study
has been performed that demonstrates the relationship between
the progression of renal disease and the degree of hyperlipidemia
in either diabetic or nondiabetic patients.
Therapeutic trials aimed at reducing circulating lipids have, in
large part, been short-term studies designed more to evaluate
safety and efficacy of a diet or a specific antilipemic agent [11]. In
diabetic and nondiabetic patients, antilipemic agents have been
effective in reducing cholesterol; specific recommendations for a
Table 1. Animal models of lipid-induced renal injury
Renal
Models damage
Dietary-induced hyperlipidemia +a
Rat +
Guinea pig +
Rabbit +
Diet-induced hyperlipidemia and another underlying disorder
Rat, unilateral nephrectomy + +
Rat, clip hypertension
Clipped kidney +
Unclipped kidney + + +
Genetic hyperlipidemia
Obese Zucker rat + +
Spontaneous hypertensive obese rat + + +
Secondary hyperlipidemia
DahI salt-sensitive rat + +
Rat, remnant kidney model + +
Rat, chronic nephrosis ++
a Abbreviations: +, moderate; ++, intermediate; ÷ ++, severe.
given class of agents are best determined by the type of abnor-
mality in the lipid profile of the patient. In the patient discussed
today, a low dose of a 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor was selected. Data from clinical
trials would lead one to expect a significant reduction in LDL
cholesterol, probably a smaller decrease in triglycerides, and a
modest increase in HDL cholesterol [11]. Whether this class of
antilipemic agent will influence the rate of loss of renal function
remains to be determined. Justification for this approach can be
gathered from a number of uncontrolled preliminary reports in
diabetic and nondiabetic proteinuric patients with progressive
renal disease [35—38]. These studies generally have used HMG-
CoA reductase inhibitors and have demonstrated a reduction in
circulating cholesterol levels and stabilization or improvement of
renal function [35—38]. As I mentioned earlier, the impact of these
agents on cardiovascular disease is unknown.
Modulation of glomerular injury by lipids: Experimental insights
As I stated at the outset, experimental investigations have
suggested that lipids are involved in renal injury (Table 1). First,
studies in several animal models of renal disease have demon-
strated an association between circulating cholesterol levels and
indices of gbomerular injury, including the degree of glomerulo-
sclerosis, mesangial expansion, and hyalinosis [39]. These studies
also demonstrated a highly significant relationship between cho-
lesterol and gbomerular deposits of lipids [39]. Indeed, failure to
detect gbomerular lipid deposits was associated with minimal
glomerulosclerosis despite hypercholesterolemia [40]. These stud-
ies provide only a useful framework for conceptualizing the
pathogenetic events that might have contributed to glomerulo-
sclerosis and do not indicate causality.
More direct evidence that hyperlipidemia can contribute to
gbomerular injury has come from studies of diet-induced hyper-
cholesterolemia in a variety of normal animals. In our studies,
feeding rats a 4% cholesterol-supplemented diet for 3 months
resulted in glomerular enlargement, mesangial expansion and
hypercellularity, albuminuria, and a modest degree of focal gb-
merulosclerosis [41]. The expanded mesangial matrix was consti-
tuted primarily by type-IV collagen, fibronectin, and laminin [42].
The increased mesangial cellularity was in part a result of an
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Table 2. Lipid-lowering agents that have reduced renal injuiy in
different animal models
Drug Animal model
Cholestyramine Chronic puromycin nephrosis
Clofibrate Remnant kidney model
Obese Zucker rat
Lovastatin Chronic puromycin nephrosis
Remnant kidney model
Obese Zucker rat
Dahi salt-sensitive rat
Probucol Chronic puromycin nephrosis
Remnant kidney model
increased influx of macrophages, which preceded mesangial ex-
pansion and albuminuria [42]. Foam cells also were evident, as
was an increased glomerular deposition of lipids. Biochemical
analysis of glomerular lipids demonstrated an increased concen-
tration of cholesterol esters and a reduced concentration of
polyunsaturated fatty acids; these findings suggested the presence
of oxidatively modified lipids [41]. Although the degree of renal
injury seen in these studies was modest, it indicated a potentially
important relationship between lipids and the glomerular recruit-
ment of macrophages as well as glomerular mesangial cell prolif-
eration. In addition, these studies suggested a relationship be-
tween hypercholesterolemia and accumulation of glomerular
matrix proteins, as well as a potential role for oxidatively modified
lipids in progressive glomerular injury. When diet-induced hyper-
cholesterolemia was combined with hypertension in rats with
Goldblatt hypertension or in hypertensive DahI salt-sensitive rats,
glomerular injury markedly increased [43, 44]. Similarly, reduc-
tion in nephron number [41] or induction of the nephrotic
syndrome by puromycin aminonucleoside [45] was associated with
exacerbation of glomerular injury in cholesterol-fed rats.
A third series of experiments that has supported a role for
hyperlipidemia in progressive renal injury involves investigations
in which lipid-lowering agents were used (Table 2). In the
remnant kidney model of progressive renal failure, induced by
surgical removal of 80% to 90% of renal mass, hypertension,
proteinuria, mesangial expansion, and increased mesangial cellu-
larity all occurred prior to the development of glomerulosclerosis.
Treatment with either an HMG-CoA reductase inhibitor or
clofibric acid reduced serum lipids, diminished albuminuria, de-
creased mesangial cellularity and matrix expansion, and signifi-
cantly reduced the incidence of glomeruloscierosis [46—49]. The
effects of these agents occurred independently of any influence on
systemic or glomerular hypertension, thus suggesting a mecha-
nism of action independent of lowering of blood pressure. Pro-
bucol, a cholesterol-lowering drug with antioxidant properties,
also ameliorated renal injury in this experimental model, and thus
raised a potentially important pathogenetic role for oxidant injury
[50].
In the obese Zucker rat, a model of endogenous hyperlipidemia
with features similar to non-insulin-dependent diabetes mellitus,
mesangial expansion, increased mesangial cellularity, increased
glomerular macrophages, glomerular lipid deposits, and albumin-
uria also precede the development of glomerulosclerosis [51]. In
this model, anti-lipemic therapy also reduced lipids, mesangial
expansion and cellularity, and the incidence of glomerulosclerosis
[47]. Again, these actions of anti-lipemic drugs occurred indepen-
dently of systemic or glomerular hemodynamic effects, thus
suggesting a nonhemodynamic role for lipids in the development
of glomerular injury in this model [47, 52]. To better assess the
potential interactions between the glomerulus and cholesterol,
investigators recently have directed their attention to evaluating
the interactions between mesangial cells and lipids. Wide-ranging
in-vitro studies have shed light on the interactions between
mesangial cells and lipids. Many of these interactions are summa-
rized in Figure 2.
Influence of lipids on mesangial cell proliferation. Glomerular
mesangial and epithelial cells possess receptors for LDL [53—57].
The binding of LDL to these cells, saturable at 4CC, is inhibitable
by heparin and excess LDL; the process is similar to the LDL
receptor binding observed in other cells [53, 56]. In addition, LDL
binds to many discrete membrane sites that aggregate and are
internalized [53}. These observations are consistent with the
process of receptor-mediated endocytosis of receptor-bound LDL
and intracellular endosomal and lysosomal processing as de-
scribed for LDL receptors in other cells [53]. Regulation of
expression of the LDL receptor on mesangial cells has not been
extensively evaluated, but inhibitors of intracellular cholesterol
synthesis upregulate HMG-CoA reductase. Thus, the LDL recep-
tor likely is also upregulated [58].
Whether mesangial cells possess the so-called "scavenger"
receptor is still debated, as binding or internalization of acetylated
or oxidized LDL by human mesangial cells was not demonstrated
[53]. Binding and uptake of oxidized LDL by rat mesangial cells
has been observed, however [53]. Moreover, mRNA for a "scav-
enger" receptor has been detected in rat mesangial cells [53].
Whether injured mesangial cells increase expression of this recep-
tor is unknown.
Exposure of mesangial cells to LDL appears to evoke a
proliferative response (Fig. 2). This proliferation is particularly
evident when other growth-promoting factors are present in the
tissue-culture medium. An increase in thymidine incorporation
accompanied by an increase in mesangial cell number has been
consistently observed when mesangial cells are exposed to con-
centrations of LDL as high as approximately 100—150 Wml [55,
58, 59]. In addition, LDL stimulation of the expression of early
nuclear response genes c-fos and c-jun has been described [55].
Increased expression of mRNA for platelet-derived growth factor
(PDGF) has been observed in mesangial cells exposed to LDL
[55]. Synergistic interactions between LDL and growth-promoting
cytokines such as endothelin, PDGF, and IGF-1 (insulin-like
growth factor) further support a role of LDL in modulating
mesangial cell proliferation [55]. The recent demonstration that
PDGF may play a role in mesangial cell proliferation leading to
glomerulosclerosis in vivo further underscores the potential im-
portance of these interactions between lipids and growth factors
[60, 61].
Influence of lipids on glomerular macrophage recruitment. Previ-
ous studies have suggested a relationship between an influx of
macrophages and the development of renal disease [62]. We also
know that hypercholesterolemia aggravates glomerular macro-
phage influx in a variety of experimental diseases [63]. Moreover,
diet-induced hypercholesterolemia also is associated with a
prompt increase in glomerular macrophages [42]. Rovin and Tan
recently evaluated the effect of LDL cholesterol on mesangial cell
production of a potent monocyte chemotactic factor, monocyte
chemoattractant protein (MCP-1) [63]. In these experiments LDL
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cholesterol increased the expression of MCP-1 mRNA, as well as
the secreted protein in a dose-dependent manner [63]. Prelimi-
nary studies from our laboratory have suggested that minimally
oxidized LDL also stimulates expression of MCP-1 mRNA by
human fetal mesangial cells (unpublished observations). These
studies suggest that one mechanism whereby hyperlipidemia
might influence glomerular injury is through recruitment of
macrophages, possibly mediated by increased MCP-1 production
(Fig. 2).
Influence of lipids on mesangial matrix. Mesangial matrix expan-
sion occurs in lipid-mediated glomerular injury, and antilipemic
therapy reduces the degree of mesangial expansion [1, 42]. These
data collectively suggest that lipids might modulate accumulation
of matrix proteins. Whether this modulation was a direct effect of
lipids on mesangial cell matrix production and/or degradation, or
an indirect effect possibly mediated through macrophage recruit-
ment, is unknown. In one recent study, the addition of LDL to
mesangial cell cultures increased mRNA for, and synthesis of,
flbronectin [63]. We have evaluated the effect of LDL alone and
LDL in concert with IGF-1 on mRNA expression of proteins
involved in the synthesis and degradation of type-IV collagen and
found that each substance alone increased mesangial cell a1 chain
type-IV collagen mRNA, but that the two together did not cause
an additive stimulation of its expression (unpublished observa-
tions). Moreover, mesangial cells exposed to IGF-1 and LDL
alone or in combination displayed an increase in a tissue inhibitor
of metalloproteinases (TIMP-2) without producing any effect on
the mRNA for the 72 kD collagenase for type-IV collagen. These
results suggest that LDL alone or in concert with IGF-1 influences
mesangial cell type-IV collagen synthesis as well as its degradation
(Fig. 2). The influence of LDL in concert with other cytokines that
influence mesangial expansion such as PDGF or TGF-/3 remains
to be established. However, it has been shown in hypercholester-
olemic nephrotic rats that increased glomerular fibronectin
mRNA expression is associated with increased TGF-13 expression
by infiltrating macrophages [64].
Oxidative modification of LDL by mesangial cells. Recent studies
Fig. 2. The effect of hyperlipidemia on
glomeruloscierosis. Low-density lipoprotein
(LDL) can be taken up by mesangial cells and
induce mesangial cell proliferation and
production of macrophage chemotactic factors.
Macrophages as well as mesangial cells can
oxidize LDL, thereby leading to the formation
of foam cells. Different products released by
macrophages and/or foam cells lead to
mesangial cell toxicity. Oxidized LDL also has
been shown to be injurious to mesangial cells.
Conversely, lipid-induced endothelial
dysfunction can contribute to altered vascular
tone and increased glomerular pressure, which
can further modify mesangial cell biology. The
increased cellularity and expanded mesangial
matrix are the pathologic hallmarks of
glomerulosclerosis. (Adapted with permission
from Curr Opiñ Nephrol Hypertens 2:372—379,
1993.)
suggest that modifications (especially by oxidation) in the struc-
ture of lipoproteins can affect the potential for vascular injury [65,
66]. Indirect evidence implies that modification of LDL might
participate in glomerular injury. These lines of evidence include
an increased concentration of cholesterol esters in cortical tissue
of hypercholesterolemic rats and guinea pigs; increased glomeru-
lar foam cells in proteinuric renal diseases and in cholesterol-fed
rats; and increased glomerular deposition of apolipoproteins and
oxidized lipoproteins in hypercholesterolemic rats with nephrotic
syndrome secondary to the puromycin aminonucleoside [1, 2, 67].
Monocyte/macrophages have been shown to oxidatively modify
LDL [68]. Recently, it has been demonstrated that proliferating
mesangial cells can oxidatively modify LDL by a mechanism that
involves generation of reactive oxygen species [58, 59]. It is
interesting that oxidized LDL inhibited mitogen-induced mesang-
ial cell proliferation [58, 59]. In addition, oxidized LDL is a
chemoattractant for macrophages and can induce MCP-1 mRNA
in a variety of cell types [68]. The precise role that oxidized LDL
plays in experimental models of progressive renal disease is
unclear but, as I mentioned earlier, the use of antioxidants such as
probucol has been associated with amelioration of renal injury
[50].
Effects of lipid-lowering agents on mesangial cells. Antilipemic
agents, such as HMG-CoA reductase inhibitors, reduce circulat-
ing lipids, and this reduction is associated with a proportional
amelioration of glomerular injury. Whether this class of agents
influences cellular processes associated with injury has only
recently begun to be explored. Inhibitors of the enzyme HMG-
CoA reductase, such as lovastatin, block the intracellular produc-
tion of mevalonate and its metabolites (Fig. 3). Products of
intracellular mevalonate metabolism are critical for the growth
and proliferation of eukaryotic cells [69]. These products include
cholesterol and several nonsterol isoprenoids. The isoprenoid
farnesyl, a particularly important intermediate in the mevalonate
pathway, can be used to synthesize cholesterol and also can bind
covalently to several low-molecular-mass GTP-binding proteins
such as p21 ras. Farnesylated p21 ras might be critical for
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mitogenic signaling stimulated by growth factors such as PDGF
[70]. In addition, this farnesylated p21 ras-growth factor receptor
complex appears to activate nuclear transcription factors such as
NF-KB and NF-IL-6 (Fig. 4), which are involved in the regulation
of gene expression for MCP-1 and IL-6 [71]. We recently dem-
onstrated that lovastatin inhibited serum-induced proliferation of
mesangial cells [72]. Lovastatin inhibition was reversed by the
simultaneous addition of either mevalonate or farnesol, but not by
exogenous LDL cholesterol. We have also demonstrated that
lovastatin inhibits PDGF-induced mesangial cell mitogenesis and
that this inhibition could be reversed by either mevalonate or
farnesy! pyrophosphate [73]. Additional support for a role of this
isoprenoid in modulating the mitogenic effect of PDGF comes
Fig. 3. The mevalonate pathway. Mevalonate is
synthesized from acetyl coenzyme A,
phosphoiylated to produce mevalonate
diphosphate (not shown), and then metabolized
to a series of isoprenoid intermediates. Farnesyl
diphosphate occupies an important central
location in the pathway, being routed to many
end products necessary for cell viability and
proliferation. (Reprinted from Ref. 71; © S.
Karger AG, Base!.)
from experiments in which mesangial cells were treated with
perillic acid, which inhibits farnesylation of intracellular proteins
such as p21 ras. In these studies, perillic acid caused a significant
dose-dependent inhibition of PDGF-stimulated DNA synthesis.
Because serum-induced mesangial cell mitogenesis also influ-
ences nuclear transcription factors involved in cellular expression
of MCP-1 and IL-6, we also evaluated the influence of lovastatin
on mesangial cell production of MCP-1 and IL-6. Lovastatin
significantly inhibited both MCP-1 and IL-6 mRNA expression
and secretion of the proteins in a dose-dependent manner [74].
These effects were reversed by exposure of mesangial cells to
exogenous mevalonate. By contrast, doses of lovastatin that
markedly inhibited MCP-1 and IL-6 production had no effect on
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mesangial cell expression of TGF-/3 [74]. These data suggest that
the in-vivo beneficial effects of lovastatin in models of renal
disease might be related, in part, to this agent's ability to
ameliorate glomerular macrophage recruitment and to modulate
the mesangial cell's proliferative response to mitogenic cytokines.
Summaiy
In summary, increasing clinical data suggest a relationship
between progressive, proteinuric renal disease and abnormal lipid
metabolism. These lipid abnormalities might contribute not only
to the increased prevalence of cardiovascular disease in these
patients, but also to the progressive loss of renal function.
Experimental data supporting this concept have rapidly expanded,
but studies to test this hypothesis in humans are lacking.
Questions and answers
DR. NIcoIAos E. MIAs (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): In view of the
similarities between atherosclerosis and glomerulosclerosis, could
you summarize for us what's known about the LDL receptor and
its regulation in the mesangial cell and the glomerular foam cell?
DR. KEANE: The LDL receptor is present on both rat and
human mesangial cells. The regulation of the LDL receptor
appears to be similar to the regulation of the LDL receptor that
is present in other cell types (for example, hepatocyte, peripheral
blood mononuclear cells), and it appears to be tightly linked to
HMG-CoA reductase activities. As you might expect, inhibition of
HMG-CoA reductase enzymes upregulates the LDL receptor in
both glomerular mesangial and epithelial cells.
Foam cells are derived from peripheral blood mononuclear
cells and behave in a different fashion than do purified, normal
monocytes. Their ability to generate cytokines and various eico-
sanoid mediators appears to be increased compared to normal
monocytes. The foam cell might have some important biologic
effects within the glomerulus. Jonathan Diamond recently dem-
onstrated in-vivo function of monocytes (using immunohisto-
chemical stains for a variety of cytokines) in experimental models
of proteinuric renal diseases in which lipids appear to play a role
[64].
DR. MADIAS: Is the mechanism of oxidation of LDL by the
mesangial cell similar to that described in other cells?
DR. KEANE: Proliferating mesangial cells probably can oxidize
native LDL. The oxidation of LDL by mesangial cells appears to
be related to the generation of free radicals, particularly super-
oxide and hydroxyl molecules. The mechanism of formation of
free radicals by mesangial cells is not completely understood. Both
the lipoxygenase pathway and the CP450 oxidative pathway have
been proposed as potential mechanisms.
DR. MADIAS: Recognizing that mesangial hypercellularity is not
equivalent to mesangial proliferation, could you expand on the
nature of the hypercellularity observed in animal studies of
diet-induced hypercholesterolemia, namely, on the time course of
the appearance of mesangial proliferation and macrophage infil-
tration?
DR. KEANE: I can only comment on the infiltrating monocytes.
This infiltration occurs within 7 days after initiation of a choles-
terol-rich diet. Whether mesangial cells are proliferating before
the influx of monocytes is unknown.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-Wellesley
Hospital, Newton, Massachusetts): Could you expand on your
comments regarding Keilani's study of the effects of fosinopril
[16]? I'm not sure I understood the observations. Second, what is
your understanding of the mechanisms of those observations?
Dn. KEANE: The point of those observations was related to the
role of proteinuria in causing lipid abnormalities. Proteinuria
induces an abnormality that affects the synthesis and degradation
of lipoproteins. Reduction in proteinuria, in this case by an ACE
inhibitor, reduced the hyperlipidemia independent of effects on
serum albumin.
DR. HARRINGTON: Where precisely does the ACE inhibitor act
in this regard?
DR. KEANE: I think the modulation occurs because of its effect
on reducing proteinuria. I'm unaware of any other effects of ACE
inhibitors directly on lipid metabolism.
DR. 1-IARRINOT0N: Ten to 15 years ago, we were first told about
the potential beneficial effect of protein restriction in renal
disease. Given the relative failure of the recently completed
MDRD study, what will it take to prove that lowering serum lipid
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Fig. 4. Relationship between isoprenoid
intermediates and cell signaling i' growth factors,
that is, PDGF. Inhibition of HMG-CoA
reductase by lovastatin might influence
mesangial cell proliferation by reducing such
isoprenoid intermediates as farnesyl
pyrophosphate (PP), thereby reducing
farnesylation of proteins such as p21 ras
necessary for the initial signal transduction by
certain growth factor receptors.
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levels has a beneficial effect on the progression of renal disease?
What study would you envisage?
DR. KEANE: I could envision a study performed in high-risk
patients, that is, patients at increased risk for progression such as
those with substantial proteinuria and hyperlipidemia. This group
might be the ideal subset of patients to study. The MDRD data
should provide us with risk factors and, perhaps, let us know which
patients are consistently rapid progressors. In this time of health
care reform, however, we might not have the money available for
large trials. My bias would be to do a limited trial with a
well-defined population that has well-defined risk factors.
DR. MADIAs: One would anticipate that experimental impair-
ment of antioxidant defense mechanisms would aggravate the
glomerulosclerosis resulting from feeding cholesterol-rich diets.
Have such studies been done?
DR. KEANE: Rats fed a vitamin E- and selenium-deficient diet,
which depletes antioxidant defenses, are at increased risk for
developing lipid-induced vascular injury [75]. Whether this in-
creases renal injury has not been completely evaluated.
DR. ANDREW KING (Division of Nephrology, New England Med-
ical Center): One example of a high LDL state in humans is type-i
hypercholesterolemia, in which the LDL cholesterol receptor is
absent. Although these patients have accelerated atherosclerosis,
they have no major glomerular lesions. Is this because they don't
have primary renal disease, glomerular injury, or some other
factor? I am also interested in other forms of human hyperlipid-
emia, some of which are associated with glomerular changes, but
most of which are not.
DR. KEANE: Lipids do not appear to be an initiator of clinically
overt renal disease. But I'm not convinced that hyperlipidemia in
humans does not induce any changes within the glomerulus at all.
A number of years ago Bert Kasiske looked at hypercholesterol-
emia and atherosclerosis and found a significant correlation
between hypercholesterolemia and the development of global
glomerular sclerosis [76]. Another piece of information, in the
diabetic literature, is the relationship between heart disease in the
parents and diabetic nephropathy in the children [77]. This gives
some credibility to the hypothesis that the abnormal metabolic
milieu of hyperlipidemia might facilitate the development of both
atherosclerosis and glomerulosclerosis.
DR. HARRINGTON: You reviewed the studies investigating the
effects of LDL on mesangial cell proliferation. Do you have
comparable studies on macrophages?
DR. KEANE: We have not studied the macrophage from glomer-
uli. Macrophages have LDL receptors and behave similarly to
other cells. I am unaware of data that have evaluated the effects of
HMG-CoA reductase inhibitors on glomerular macrophage func-
tion.
DR. HARRINGTON: Do you have a direct way of reducing Lp(a)
without affecting other cholesterol abnormalities?
DR. KEANE: I wish I did. Nicotinic acid has been used. A
number of ongoing studies are looking at the newer fibrate
derivatives to see how they might influence Lp(a). Most of the
antilipemic agents do not have a significant effect on Lp(a).
Reduction of proteinuria has been associated with a reduction in
Lp(a), together with other lipids.
DR. BRIAN PEREIRA (Division of Nephrology, New England
Medical Center): In some of the studies that you discussed, high
lipid levels were associated with progression of renal disease. Is
proteinuria, which also was associated with progressive renal
disease, an independent risk factor?
DR. KEANE: In the studies reported to date, hypertension and
hyperlipidemia were identified as independent risk factors by
multivariate analysis. The dyslipidemia also was independent of
proteinuria. The MDRD study will provide additional insights in
this regard.
DR. PEREIRA: Is it possible that the elevated lipid levels are
immunostimulatory as far as peripheral blood mononuclear cells
are concerned? In that case, anti-lipid strategies would exacerbate
the immunodeficiency of uremia.
DR. KEANE: I don't know. I'm unaware of any studies of the
immune response in patients who have hyperlipidemia.
DR. AJAY SINGH (Division of Nephrology, New England Medical
Center): You postulated that lipids modulate mesangial cell
proliferation through the secretion of a variety of cytokines,
including IL-6. Could you review the mechanisms by which lipids
might modulate the regulation and secretion of inflammatory
cytokines? Are other cells, such as macrophages, involved in this
response? Is activation by IgG immune complexes binding to Fc
receptors on mesangial cells a prerequisite for lipid-induced
mesangial cell cytokine release?
DR. KEANE: Lipids appear to function as a competence factor
for a variety of cytokines that induce proliferation of mesangial
cells. As such, many of these cytokines can induce, in an autocrine
manner, mesangial cell production of these cytokines. It is also
clear that macrophages are involved in the initial production of
these inflammatory mediators. What is unknown is how these
mediators are chronically produced and by what cell type. I
suspect that an initial toxic or immunologic insult in the glomer-
ulus is the first step, which is followed by an influx of inflammatory
cells. The stimulus for this influx might be mesangial cell release
of certain inflammatory cytokines, for example, MCP-i or CSF.
These macrophages possibly amplify any inflammatory response
and ultimately lead to resolution of the disease. In some settings,
however, resolution does not occur and chronicity leads to
nephron loss. It is unclear at present what leads to this chronic
progressive phase. As I suggested, modified lipids could be one
such factor; it would appear that they can stimulate production of
key cytokines such as TGF-f3.
DR. SINGH: Does regulation of TGF-p involve the HMG-CoA
reductase pathway?
DR. KEANE: No. There is no evidence that inhibition of
HMG-CoA reductase modifies expression of TGF-j3 by mesangial
cells.
DR. SINGH: How, then, does lovastatin, an HMG-CoA reduc-
tase inhibitor, modulate TGF-f3 gene regulation? Is there another
pathway?
DR. KEANE: It is possible that lovastatin influences macrophage
recruitment by its ability to decrease MCP-i production. This, in
turn, could influence macrophage production of TGF-13 in the
glomerulus indirectly.
DR. RICHARD LAFAYETI'E (Division of Nephrology, New England
Medical Center): The ability of anti-lipemic therapy to be antipro-
liferative might allow it to protect against renal injury by reducing
glomerular hypertrophy. Has a reduction in glomerular hypertro-
phy been found in studies of progressive renal disease when
anti-lipemic therapy is used?
DR. KEANE: We have looked at glomerular hypertrophy. Our
results are not impressive in terms of reducing compensatory
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hypertrophy. Reduction of hypertrophy doesn't seem to be a
major component of the mechanism of action of these anti-
lipemic agents.
DR. MiAs: Are there comparative studies on the salutary
effects on the kidney of a nonabsorbable hypolipemic agent, such
as cholestyramine versus HMG-CoA reductase inhibitors, that
weigh the relative importance of the nonhypocholesterolemic
effects of the latter class of agents?
DR. KEANE: Cholestyramine has been used, and this agent has
reduced glomerular injury. I'm not sure whether solid compara-
tive studies are available.
DR. JULIA NEURINGER (Division of Nephrology, New England
Medical Center): You showed that lovastatin reduces intimal
proliferation in the aorta in a model of chronic vascular rejection.
Are you aware of any data showing a correlation between
cholesterol levels and progression in renal transplant patients?
Have you tried giving lovastatin to any of your patients?
DR. KEANE: Kasiske's study looked at risk factors for chronic
renal rejection and found an association with cholesterol levels
and evidence for chronic rejection one year post transplantation
[78]. He currently has a prospective trial of an HMG-CoA
reductase inhibitor in transplant patients, but I have no results to
date.
DR. MADIAS: Can you give us your recommendations about
treating the dyslipidemia of the nephrotic syndrome and that of
chronic renal failure?
DR. KEANE: I've given my bias with transplant patients because
cardiovascular disease and chronic vascular rejection are the most
important complications in the transplant patient, and hypercho-
lesterolemia is common in these patients. I believe it is appropri-
ate to treat these patients with an HMG-CoA reductase inhibitor.
In patients with chronic, persistent proteinuria and hypercholes-
terolemia, my own prejudice is that we should treat unless there is
a contraindication. While others have successfully reduced cho-
lesterol levels by dietary modification in patients with the ne-
phrotic syndrome, we have been relatively unsuccessful in chang-
ing hypercholesterolemia with our dietary approaches. We do use
dietary modification, but we usually add low doses of an HMG-
CoA reductase inhibitor after attempting to reduce proteinuria.
DR. SVETLOZAR N. NATOV (Clinical Research Fellow, Division of
Nephrology, New England Medical Center): Cyclosporine is known
to disturb the balance between vasodilatory and vasoconstrictive
eicosanoids [79] and to cause hypertriglyceridemia [80]. At the
same time, omega-3 polyunsaturated fatty acids (fish oil) have
been found of therapeutic benefit in CsA-treated renal transplant
recipients and in patients with chronic glomerular disease, prob-
ably because these compounds have favorable effects on prostag-
landin synthesis and lipid metabolism [81, 82]. Would you give us
your experience with fish oil in renal diseases and, more particu-
larly, in cyclosporine-treated transplant recipients?
DR. KEANE: I don't have any personal experience using fish oils
in patients with renal disease. A number of reports show that fish
oils have benefit in a variety of different diseases, one of which is
cyclosporine-induced injury. How the fish oils work is unclear.
There is no question that in animals and humans the oils affect
circulating lipids, particularly circulating triglyceride levels. Fish
oils also have a host of effects on eicosanoid production and
cytokine production, which, in turn, may influence and modulate
renal injury.
Reprint requests to Dr. W. Keane, Department of Medicine, Division of
Nephrology, Hennepin County Medical Center, 701 Park Avenue South,
Minneapolis, Minnesota 55415, USA
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